Kisspeptin

Kisspeptin Nasal Spray is supplied as a catalogued research material in the presentation nasal spray, 10mg/10ml. This description distinguishes the peptide identity from the finished formulation; batch-specific composition and analytical documentation should be confirmed against the matching Certificate of Analysis (CoA) and Safety Data Sheet (SDS).

The catalogue compound corresponds to human Kisspeptin-10 (KP-10), the amidated C-terminal decapeptide of the KISS1 precursor. Kisspeptin is a family designation rather than a unique material identity. Confirmation of sequence, terminal amidation, salt or counter-ion and formulation composition is necessary before applying compound-specific registry information to an individual batch.

Chemical properties and registry information

Peptide registry identifiers and molecular properties describe the matching compound, not the complete nasal spray formulation. Batch records take precedence over family-level identity assumptions.

Research background and published evidence

Published research

KISS1-derived peptides, including Kisspeptin-10, have been studied as ligands of the KISS1R/GPR54 receptor in receptor, cellular and physiological research. Published work addresses peptide–receptor recognition and kisspeptin signalling. Longer peptides, including Kisspeptin-54, -14 and -13, share the C-terminal decapeptide core but remain distinct molecular materials with different structural and analytical characteristics.

Current scientific understanding

Interpretation depends on the peptide isoform, species sequence, terminal form, experimental matrix and assay. A shared C-terminal RFamide motif does not establish analytical interchangeability. Evidence concerning a defined peptide in a particular experimental system should therefore be distinguished from evidence concerning a finished formulation. Receptor-level findings alone do not characterise this nasal spray or establish its behaviour in other research settings.

Formulation note

Published research predominantly concerns other research materials and experimental routes rather than this catalogue nasal spray. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Excipients, formulation matrix and peptide integrity are separate considerations requiring formulation-specific evidence. The catalogue strength identifies the supplied presentation; it does not establish comparability with materials described in published studies.

Quality and testing

Quality documentation must be specific to the supplied presentation and batch. Consult the matching CoA for reported identity, analytical methods, acceptance criteria and results, with the SDS providing supporting material information. A report for an unformulated peptide or another presentation should not be treated as documentation for this finished product.

Chromatographic purity, molecular identity, net peptide content, formulation composition, sterility, endotoxin and elemental impurities are separate attributes. One measurement does not establish the others, and unreported attributes should not be assumed to have been tested.

For laboratory research use only by qualified professionals. Not for human or veterinary use. No dosing or administration directions are provided.